Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
The global average price of Interferon Alpha-2a Biosimilar is in the decreasing trend, from 186.78 USD/Unit in 2013 to 64.67 USD/Unit in 2017. With the situation of global economy, prices will be in decreasing trend in the following five years.
The classification of Interferon Alpha-2a Biosimilar includes ordinary type and long-lasting type, and the proportion of ordinary type in 2017 is about 64%, and the proportion is in increasing trend from 2013 to 2017.
Interferon Alpha-2a Biosimilar is widely used for hepatitis C, hepatitis B and other diseases. The most proportion of Interferon Alpha-2a Biosimilar is used for hepatitis C, and the proportion in 2017 is 46%.
Europe is the largest supplier of Interferon Alpha-2a Biosimilar, with a production market share nearly 70% in 2017.
South America is the largest consumption place, with a consumption market share nearly 26% in 2017. Following South America, Europe is the second largest consumption place with the consumption market share of 22%.
Market competition is not intense. Roche, Biosidus, Zydus Cadila, Nanogen, Amega Biotech, Rhein Minapharm Biogenetics, PROBIOMED, 3sbio, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The global Interferon Alpha-2a Biosimilar market is valued at 390 million US$ in 2018 is expected to reach 150 million US$ by the end of 2025, growing at a CAGR of -11.0% during 2019-2025.
This report focuses on Interferon Alpha-2a Biosimilar volume and value at global level, regional level and company level. From a global perspective, this report represents overall Interferon Alpha-2a Biosimilar market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
Roche
Biosidus
Zydus Cadila
Nanogen
Amega Biotech
Rhein Minapharm Biogenetics
PROBIOMED
3sbio
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Long-lasting Type
Ordinary Type
Segment by Application
Hepatitis C
Hepatitis B
Other
Summary:
Get latest Market Research Reports on Interferon Alpha-2a Biosimilar . Industry analysis & Market Report on Interferon Alpha-2a Biosimilar is a syndicated market report, published as Global Interferon Alpha-2a Biosimilar Market Research Report 2019. It is complete Research Study and Industry Analysis of Interferon Alpha-2a Biosimilar market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.